122 related articles for article (PubMed ID: 24374277)
1. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G
Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
4. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.
Simonsen KB; Juhl K; Steiniger-Brach B; Nielsen SM
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):379-88. PubMed ID: 20597024
[TBL] [Abstract][Full Text] [Related]
5. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.
Sanger GJ
Br J Pharmacol; 2004 Apr; 141(8):1303-12. PubMed ID: 15023866
[TBL] [Abstract][Full Text] [Related]
6. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
Dawson LA; Porter RA
Future Med Chem; 2013 Sep; 5(13):1525-46. PubMed ID: 24024945
[TBL] [Abstract][Full Text] [Related]
7. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
[TBL] [Abstract][Full Text] [Related]
8. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
11. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a novel class of non-peptide NK-2 receptor ligand, derived from 1-phenyl-3-pyrrol-1-ylindan-2-carboxamides.
Guillon J; Dallemagne P; Léger JM; Sopkova J; Bovy PR; Jarry C; Rault S
Bioorg Med Chem; 2002 Apr; 10(4):1043-50. PubMed ID: 11836113
[TBL] [Abstract][Full Text] [Related]
13. Neurokinin receptor antagonism: a patent review (2014-present).
Muñoz M; Coveñas R
Expert Opin Ther Pat; 2020 Jul; 30(7):527-539. PubMed ID: 32401556
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists.
Xiong H; Kang J; Woods JM; McCauley JP; Koether GM; Albert JS; Hinkley L; Li Y; Gadient RA; Simpson TR
Bioorg Med Chem Lett; 2011 Mar; 21(6):1896-9. PubMed ID: 21320776
[TBL] [Abstract][Full Text] [Related]
15. Osanetant Sanofi-Synthélabo.
Kamali F
Curr Opin Investig Drugs; 2001 Jul; 2(7):950-6. PubMed ID: 11757797
[TBL] [Abstract][Full Text] [Related]
16. Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.
Ratni H; Ballard TM; Bissantz C; Hoffmann T; Jablonski P; Knoflach F; Knust H; Malherbe P; Nettekoven M; Patiny-Adam A; Riemer C; Schmitt M; Spooren W
Bioorg Med Chem Lett; 2010 Nov; 20(22):6735-8. PubMed ID: 20850972
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia.
Dawson LA; Smith PW
Curr Pharm Des; 2010 Jan; 16(3):344-57. PubMed ID: 20109143
[TBL] [Abstract][Full Text] [Related]
18. Distinct regional distributions of NK1 and NK3 neurokinin receptor immunoreactivity in rat brainstem gustatory centers.
Harrison TA; Hoover DB; King MS
Brain Res Bull; 2004 Mar; 63(1):7-17. PubMed ID: 15121234
[TBL] [Abstract][Full Text] [Related]
19. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
20. 3D-Quantitative structure-activity relationship and docking studies of the tachykinin NK3 receptor.
Geldenhuys WJ; Simmons MA
Bioorg Med Chem Lett; 2011 Dec; 21(24):7405-11. PubMed ID: 22056747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
